BrosMed Medical Advances to Inquiry Stage in ChiNext IPO Filing, Highlighting Leadership in High-Performance Vascular Interventional Devices

According to the Zhidian Finance app, on January 8, the listing review status of BrosMed Medical Co., Ltd. (referred to as "BrosMed Medical") for the ChiNext Board of the Shenzhen Stock Exchange was updated to "Under Inquiry." China International Capital Corporation Limited is its sponsor institution, and the company plans to raise 1.7 billion yuan.

According to the prospectus, BrosMed Medical focuses on the research and development, production, and global sales of high-performance vascular interventional medical devices. It is a leading provider of complex vascular disease interventional treatment solutions with advanced technology and products in the industry worldwide. Meanwhile, it is also a leading R&D and manufacturing enterprise in China in terms of production and sales in the field of balloon catheters for vascular intervention.

In terms of product system construction, the company has formed a comprehensive product matrix covering multiple treatment scenarios, with over 50 product series. The application fields of its products encompass key areas such as coronary intervention, peripheral intervention, neurointervention, hemodialysis access, and interventional accessories. These include core product lines such as various general balloon catheters, functional balloon catheters, drug-coated balloon catheters, interventional guidewires and catheters, multiple thrombectomy devices, calcification management tools, and energy-based therapeutic devices, fully meeting the diverse clinical needs for the interventional treatment of complex vascular diseases.

In terms of R&D and production layout, the company emphasizes global resource integration and production capacity assurance. It has currently established 5 R&D centers and laboratories worldwide to continuously drive core technology iteration and innovative product development; set up 4 production bases to ensure large-scale, high-quality product supply; and built 3 international operation centers to provide efficient operational support and service assurance for global market expansion.

In terms of market coverage, BrosMed Medical's products have been successfully marketed in over 100 countries and regions worldwide, serving more than ten thousand hospitals and medical centers globally. With stable product performance, systematic treatment solutions, and professional technical support, the company has established a strong brand image in the global vascular interventional medical device market, gradually building a global market presence and customer service network.

BrosMed Medical Co., Ltd. has long been practicing the integrated business development strategy of "innovation + scale + internationalization" and has grown into a fast-growing multinational platform enterprise with significant industry influence in the global vascular interventional field. "Empowering Chinese innovation and benefiting patients worldwide" is the core development concept of the company’s technological innovation and global industrialization. Since its establishment, the company has maintained high R&D investment, building a well-structured and highly efficient R&D talent team along with an IPD product development system. Relying on key research platforms such as the Guangdong Vascular Intervention Technology and Device Engineering Research Center, Dongguan Key Laboratory for Vascular Intervention Medical Device Research and Development, and CNAS-accredited laboratories, the company has achieved multiple globally recognized breakthroughs in product technology and core processes through extensive industry-university-research cooperation and medical-engineering innovation collaboration worldwide. As of the date of the prospectus signing, BrosMed Medical has launched seven products that are either globally pioneering or feature unique innovative technologies. Additionally, the company was the sole recipient of the Second Prize of the 2020 Guangdong Provincial Science and Technology Progress Award. Twelve of its products have been recognized as Guangdong High-Quality High-Tech Products, and it holds over 80 authorized domestic and international invention patents, laying a solid foundation for continuous innovation.

As a leading company in the field of vascular interventional medical devices, BrosMed Medical has gained a dominant market position through its technical advantages and scaled production capabilities in products like balloon catheters. According to Frost & Sullivan, in 2024, BrosMed Medical ranked fourth in China's coronary artery balloon dilation catheter market with a 9.6% market share, securing the top position among domestically produced brands; it also ranked fifth in China’s peripheral artery balloon dilation catheter market with a 4.7% market share.

Financially, for the years 2022, 2023, 2024, and January-June 2025, the company achieved operating revenues of approximately RMB 207 million, RMB 335 million, RMB 460 million, and RMB 303 million, respectively. During the same periods, the net profits were RMB -36.0614 million, RMB 25.9914 million, RMB 76.7847 million, and RMB 35.6496 million, respectively.